肠道微生物介导的胆代谢加剧了由慢性大脑低流引起的认知障碍
Xiao Li1, Yueran Ren1, Xuxuan Gao1
1Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
概括
肠道微生物群的胆转化为TMAO的新陈代谢会使慢性大脑低 perfusion (CCH) 和血管认知障碍 (VCI) 恶化. 减少饮食中的胆可能有助于预防CCH患者的认知衰退.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 代谢科学 代谢科学
背景情况:
- 慢性大脑缺血 (CCH) 是血管认知障碍 (VCI) 的主要驱动因素.
- 肠道微生物群的胆转化为三甲基胺N氧化物 (TMAO) 的代谢与心血管疾病和认知问题有关.
- 胆-TMAO途径在CCH诱导的VCI中的特定作用仍然不清楚.
研究的目的:
- 研究CCH患者的胆-TMAO途径和认知功能之间的关联.
- 探索胆丰富的饮食对认知障碍的影响及其机制在CCH的老鼠模型中.
主要方法:
- 一项横截面临床研究,将血胆/TMAO水平与认知评分相关联.
- 双边常 carotid 动脉封闭大鼠模型,以评估饮食胆对认知和肠道微生物群的影响.
主要成果:
- 血胆和TMAO水平与CCH患者的认知表现有负相关性.
- 富含胆的饮食在老鼠中恶化了CCH诱导的认知缺陷.
- 这种恶化与肠道胆代谢细菌的增加和TMAO生成的增加有关.
结论:
- 肠道微生物群介导的胆-TMAO通路显著导致CCH的认知障碍.
- 调节饮食中的胆摄入量,以肠道微生物群分析为指导,为缓解与CCH相关的长期认知衰退提供了一个潜在的策略.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Role of Neurotransmitters in Memory
428
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
428
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444


